Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Pretargeted radioimmunotherapy.

Ruby F Meredith1, Donald J Buchsbaum

  • 1Radiation Oncology, University of Alabama at Birmingham, Birmingham, AL, USA.

International Journal of Radiation Oncology, Biology, Physics
|September 19, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Pan-RAS Inhibitors: Expanding Therapeutic Potential and Evading Resistance.

Cancers·2026
Same author

Jump-starting the T cell response in established tumors.

bioRxiv : the preprint server for biology·2026
Same author

ADT-030, a novel PDE10 inhibitor, demonstrates potent antitumor activity in pancreatic ductal adenocarcinoma.

bioRxiv : the preprint server for biology·2026
Same author

Evaluation of a Novel Pan-RAS Inhibitor in 3D Bioprinted Tumor Models.

Cancers·2025
Same author

Editorial: RAS inhibitor therapy of cancer.

Frontiers in oncology·2025
Same author

ADT-1004: a first-in-class, oral pan-RAS inhibitor with robust antitumor activity in preclinical models of pancreatic ductal adenocarcinoma.

Molecular cancer·2025
Same journal

Single Percussive Ventilation Breath-hold Imaging and Delivery in Lung Tumor Stereotactic Ablative Radiation Therapy: Initial Observations From a Prospective Clinical Trial.

International journal of radiation oncology, biology, physics·2026
Same journal

Proton beam therapy in nonmetastatic rhabdomyosarcoma: Outcome, prognostic factors and the effect of timing of radiation therapy.

International journal of radiation oncology, biology, physics·2026
Same journal

Hypofractionated Proton Reirradiation for Recurrent Glioblastoma: Clinical and Dosimetric Outcomes from a Large Single Institution Series.

International journal of radiation oncology, biology, physics·2026
Same journal

Gastrointestinal Motility-Induced Interplay in Pancreas Proton Therapy: Motion Simulation and Dosimetric Impact.

International journal of radiation oncology, biology, physics·2026
Same journal

Intra-fractional Voxel-wise Anatomical Motion Tracking Guided by Multimodal Respiratory Surrogates in Radiotherapy: Framework Development and Multi-Center Validation.

International journal of radiation oncology, biology, physics·2026
Same journal

A Gaussian-based planning approach for robust dose-escalated stereotactic body proton therapy.

International journal of radiation oncology, biology, physics·2026
See all related articles

Pretargeted radioimmunotherapy shows promise for cancer treatment, achieving higher tumor radiation doses with less toxicity in preclinical and early clinical studies. This innovative approach enhances therapeutic outcomes by targeting tumors more effectively.

Area of Science:

  • Oncology
  • Radiopharmaceuticals
  • Immunotherapy

Background:

  • Pretargeted radioimmunotherapy (PRIT) aims to improve the therapeutic index of radiopharmaceuticals by separating the targeting and radiolabeling steps.
  • Traditional radioimmunotherapy often suffers from suboptimal tumor-to-background ratios and dose-limiting toxicities.

Purpose of the Study:

  • To review the concept and results of pretargeted radioimmunotherapy.
  • To evaluate PRIT efficacy in preclinical models and initial clinical trials.

Main Methods:

  • Utilized bifunctional antibodies or streptavidin-biotin conjugates for pretargeting.
  • Employed a clearing agent (mono-biotin poly N-acetyl-galactosamine) to remove unbound pretargeting agents.
  • Administered radiolabeled peptides or biotin for final tumor targeting and imaging/therapy.

Related Experiment Videos

Main Results:

  • Demonstrated promising therapeutic responses in preclinical tumor xenograft models.
  • Phase I trial with anti-CD20/streptavidin and 90Y-biotin showed objective responses and minimal toxicity in lymphoma patients.
  • Achieved a high average tumor-to-whole-body radiation dose ratio of 49 in the clinical study.

Conclusions:

  • Pretargeted radioimmunotherapy offers a significant advantage over one-step radioimmunotherapy by improving tumor targeting and reducing systemic radiation exposure.
  • PRIT demonstrates potential as an effective and safer cancer treatment modality.